A cell-permeable inhibitor to trap Gαq proteins in the empty pocket conformation

Chemistry and Biology

Volumn 21, Issue 7, 2014, Pages 890-902

  Schmitz, Anna Lena ^a   Schrage, Ramona ^a   Gaffal, Evelyn ^a   Charpentier, Thomas H ^b   Wiest, Johannes ^c   Hiltensperger, Georg ^c   Morschel, Julia ^a   Hennen, Stephanie ^a   Häußler, Daniela ^a   Horn, Velten ^d   Wenzel, Daniela ^a   Grundmann, Manuel ^a   Büllesbach, Katrin M ^a   Schröder, Ralf ^a   Brewitz, H Henning ^a   Schmidt, Johannes ^a   Gomeza, Jesús ^a   Galés, Céline ^e   Fleischmann, Bernd K ^a   Tüting, Thomas ^a   Imhof, Diana ^a   Tietze, Daniel ^d   Gütschow, Michael ^a   Holzgrabe, Ulrike ^c   Sondek, John ^b   Harden, T Kendall ^b   Mohr, Klaus ^a   Kostenis, Evi ^a   more..

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^e University Hospital of Toulouse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIM 46187; UNCLASSIFIED DRUG; 7-(2-AMINO-1-OXO-3-THIO-PROPYL)-8-CYCLOHEXYLMETHYL-2-PHENYL-5,6,7,8-TETRAHYDRO-IMIDAZO-(1,2A)-PYRAZINE DIMER, HYDROCHLORIDE; CYCLOHEXANE DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CONFORMATION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DIMERIZATION; DRUG EFFECTS; METABOLISM; PERMEABILITY; PROTEIN CONFORMATION;

ANIMALS; CELL LINE; CELL PROLIFERATION; CYCLOHEXANES; DIMERIZATION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; MODELS, MOLECULAR; PERMEABILITY; PROTEIN CONFORMATION; PYRAZINES; SIGNAL TRANSDUCTION;

EID: 84904538235     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.06.003     Document Type: Article

References (34)

1. A. Ahmed-Belkacem, A. Pozza, F. Muñoz-Martínez, S.E. Bates, S. Castanys, F. Gamarro, A. Di Pietro, and J.M. Pérez-Victoria Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2 Cancer Res. 65 2005 4852 4860
2. A. Ashkenazi, J. Ramachandran, and D.J. Capon Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic receptor subtypes Nature 340 1989 146 150
3. M.A. Ayoub, M. Damian, C. Gespach, E. Ferrandis, O. Lavergne, O. De Wever, J.-L. Banères, J.-P. Pin, and G.P. Prévost Inhibition of heterotrimeric G protein signaling by a small molecule acting on Galpha subunit J. Biol. Chem. 284 2009 29136 29145
4. T.M. Bonacci, J.L. Mathews, C. Yuan, D.M. Lehmann, S. Malik, D. Wu, J.L. Font, J.M. Bidlack, and A.V. Smrcka Differential targeting of Gbetagamma-subunit signaling with small molecules Science 312 2006 443 446
5. P. Chidiac, V.S. Markin, and E.M. Ross Kinetic control of guanine nucleotide binding to soluble Galpha(q) Biochem. Pharmacol. 58 1999 39 48
6. A. De Lean, J.M. Stadel, and R.J. Lefkowitz A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor J. Biol. Chem. 255 1980 7108 7117
7. C. Galés, J.J.J. Van Durm, S. Schaak, S. Pontier, Y. Percherancier, M. Audet, H. Paris, and M. Bouvier Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes Nat. Struct. Mol. Biol. 13 2006 778 786
8. M. Hohenegger, M. Waldhoer, W. Beindl, B. Böing, A. Kreimeyer, P. Nickel, C. Nanoff, and M. Freissmuth Gsalpha-selective G protein antagonists Proc. Natl. Acad. Sci. USA 95 1998 346 351
9. Y. Itoh, Y. Kawamata, M. Harada, M. Kobayashi, R. Fujii, S. Fukusumi, K. Ogi, M. Hosoya, Y. Tanaka, and H. Uejima et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40 Nature 422 2003 173 176
10. C.A. Johnston, and D.P. Siderovski Receptor-mediated activation of heterotrimeric G-proteins: current structural insights Mol. Pharmacol. 72 2007 219 230
11. C.A. Johnston, F.S. Willard, J.K. Ramer, R. Blaesius, C.N. Roques, and D.P. Siderovski State-selective binding peptides for heterotrimeric G-protein subunits: novel tools for investigating G-protein signaling dynamics Comb. Chem. High Throughput Screen. 11 2008 370 381
12. J.C. Jones, A.M. Jones, B.R.S. Temple, and H.G. Dohlman Differences in intradomain and interdomain motion confer distinct activation properties to structurally similar Gα proteins Proc. Natl. Acad. Sci. USA 109 2012 7275 7279
13. T. Kenakin, and A. Christopoulos Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat. Rev. Drug Discov. 12 2013 205 216
14. A.J. Kimple, D.E. Bosch, P.M. Giguère, and D.P. Siderovski Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets Pharmacol. Rev. 63 2011 728 749
15. E. Kostenis, L. Martini, J. Ellis, M. Waldhoer, A. Heydorn, M.M. Rosenkilde, P.K. Norregaard, R. Jorgensen, J.L. Whistler, and G. Milligan A highly conserved glycine within linker I and the extreme C terminus of G protein alpha subunits interact cooperatively in switching G protein-coupled receptor-to-effector specificity J. Pharmacol. Exp. Ther. 313 2005 78 87
16. S. Leyers, H.-G. Häcker, J. Wiendlocha, M. Gütschow, and M. Wiese A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins Bioorg. Med. Chem. Lett. 18 2008 4761 4763
17. S. Mangmool, and H. Kurose G(i/o) protein-dependent and -independent actions of Pertussis Toxin (PTX) Toxins (Basel) 3 2011 884 899
18. G. Milligan, and E. Kostenis Heterotrimeric G-proteins: a short history Br. J. Pharmacol. 147 Suppl. 1 2006 S46 S55
19. S.R. Neves, P.T. Ram, and R. Iyengar G protein pathways Science 296 2002 1636 1639
20. A. Nishimura, K. Kitano, J. Takasaki, M. Taniguchi, N. Mizuno, K. Tago, T. Hakoshima, and H. Itoh Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule Proc. Natl. Acad. Sci. USA 107 2010 13666 13671
21. W.M. Oldham, and H.E. Hamm Heterotrimeric G protein activation by G-protein-coupled receptors Nat. Rev. Mol. Cell Biol. 9 2008 60 71
22. G.P. Prévost, M.O. Lonchampt, S. Holbeck, S. Attoub, D. Zaharevitz, M. Alley, J. Wright, M.C. Brezak, H. Coulomb, and A. Savola et al. Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex Cancer Res. 66 2006 9227 9234
23. M. Rask-Andersen, M.S. Almén, and H.B. Schiöth Trends in the exploitation of novel drug targets Nat. Rev. Drug Discov. 10 2011 579 590
24. M. Rodbell, H.M. Krans, S.L. Pohl, and L. Birnbaumer The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. IV. Effects of guanylnucleotides on binding of 125I-glucagon J. Biol. Chem. 246 1971 1872 1876
25. A. Saulière, M. Bellot, H. Paris, C. Denis, F. Finana, J.T. Hansen, M.-F. Altié, M.-H. Seguelas, A. Pathak, and J.L. Hansen et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity Nat. Chem. Biol. 8 2012 622 630
26. J. Schmidt, N.J. Smith, E. Christiansen, I.G. Tikhonova, M. Grundmann, B.D. Hudson, R.J. Ward, C. Drewke, G. Milligan, E. Kostenis, and T. Ulven Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3 J. Biol. Chem. 286 2011 10628 10640
27. R. Schröder, N. Merten, J.M. Mathiesen, L. Martini, A. Kruljac-Letunic, F. Krop, A. Blaukat, Y. Fang, E. Tran, and T. Ulven et al. The C-terminal tail of CRTH2 is a key molecular determinant that constrains Galphai and downstream signaling cascade activation J. Biol. Chem. 284 2009 1324 1336
28. R. Seifert, U. Gether, K. Wenzel-Seifert, and B.K. Kobilka Effects of guanine, inosine, and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations Mol. Pharmacol. 56 1999 348 358
29. A.V. Smrcka Molecular targeting of Gα and Gβγ subunits: a potential approach for cancer therapeutics Trends Pharmacol. Sci. 34 2013 290 298
30. J. Takasaki, T. Saito, M. Taniguchi, T. Kawasaki, Y. Moritani, K. Hayashi, and M. Kobori A novel Galphaq/11-selective inhibitor J. Biol. Chem. 279 2004 47438 47445
31. M.A. Wall, B.A. Posner, and S.R. Sprang Structural basis of activity and subunit recognition in G protein heterotrimers Structure 6 1998 1169 1183
32. R.E. West Jr., J. Moss, M. Vaughan, T. Liu, and T.Y. Liu Pertussis toxin-catalyzed ADP-ribosylation of transducin. Cysteine 347 is the ADP-ribose acceptor site J. Biol. Chem. 260 1985 14428 14430
33. Y.H. Wong, A. Federman, A.M. Pace, I. Zachary, T. Evans, J. Pouysségur, and H.R. Bourne Mutant alpha subunits of Gi2 inhibit cyclic AMP accumulation Nature 351 1991 63 65
34. H.M. Wortelboer, M. Usta, A.E. van der Velde, M.G. Boersma, B. Spenkelink, J.J. van Zanden, I.M.C.M. Rietjens, P.J. van Bladeren, and N.H.P. Cnubben Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin Chem. Res. Toxicol. 16 2003 1642 1651